SLC2A1 and colorectal carcinoma: METTL3 promotes this process by stabilizing HK2 and GLUT1 mRNA through IGF2BPs-mediated m6A modification, thereby enhancing glycolytic activity and CRC cell proliferation, ultimately driving tumor progression (Shen et al., 2020).